GeneDx Study Shows Hospital-Wide Rapid Genome Sequencing Can Improve Pediatric Diagnosis, Outcomes and Health System Efficiency
GeneDx (Nasdaq: WGS), a company focused on rare disease diagnosis and the use of genomic information to improve health outcomes, has announced new findings demonstrating the potential benefits of expanding rapid genome sequencing (rGS) beyond traditional intensive care settings. The findings, published in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG), were developed in collaboration with the clinical genetics team at Seattle Children’s.
The study, titled “Hospital-wide implementation of inpatient first-tier rapid genome sequencing,” evaluated the use of rGS as a first-tier diagnostic test across a broad range of pediatric inpatient settings. Researchers examined more than 1,000 hospitalized children who underwent rapid genome sequencing over a 3.5-year period.
Patients included in the analysis were treated across several hospital units, including the neonatal intensive care unit (NICU), pediatric intensive care unit (PICU), cardiac intensive care unit (CICU) and non-critical care inpatient wards.
The results suggest that rapid genome sequencing can deliver substantial diagnostic value outside traditional intensive care environments. Overall, the study reported a diagnostic yield of 35%, while the diagnostic yield among patients in non-intensive care inpatient wards reached 43%, the highest yield reported across the hospital units evaluated.
One of the most notable findings involved children hospitalized for faltering growth. In this patient group, the diagnostic yield reached 63%, with researchers identifying 37 distinct genetic diagnoses among 36 patients. Four children were found to have dual diagnoses, demonstrating the ability of genomic testing to identify complex or overlapping genetic conditions that may otherwise remain undiagnosed.
The findings provide evidence for a broader model of genomic medicine in which rapid genome sequencing is incorporated into routine inpatient pediatric care rather than being reserved primarily for critically ill infants or children.
Expanding Rapid Genome Sequencing Beyond Intensive Care
Rapid genome sequencing has traditionally been associated with critically ill newborns and children, particularly those in intensive care units where unexplained symptoms can require urgent diagnosis.
In these circumstances, obtaining a genetic diagnosis quickly can help physicians determine appropriate treatment, avoid unnecessary testing and provide families with a clearer understanding of a child’s condition.
However, the Seattle Children’s study suggests that the value of rapid genomic testing may extend considerably further.
Tara L. Wenger, MD, PhD, noted that rGS has historically been associated with critically ill infants in intensive care settings, but the study demonstrated that children throughout the hospital may benefit from earlier genomic diagnosis.
Many pediatric patients outside intensive care can experience prolonged diagnostic journeys involving multiple specialists, laboratory tests and imaging procedures. Some may have symptoms that do not immediately suggest a genetic disorder, while others may never be referred for genetic evaluation after leaving the hospital.
By introducing rapid genome sequencing earlier during hospitalization, clinicians may have an opportunity to identify underlying genetic conditions before patients undergo lengthy and potentially fragmented diagnostic evaluations.
Strong Diagnostic Performance in Non-ICU Patients
The overall diagnostic yield of 35% demonstrates the ability of rGS to identify genetic causes of disease in a substantial proportion of hospitalized pediatric patients.
The 43% yield observed in non-ICU inpatient wards is particularly important because these patients are not necessarily considered traditional candidates for rapid genome sequencing.
Non-critical care units include children who may be medically stable compared with intensive care patients but still have unexplained or complex clinical presentations. Their symptoms may involve multiple organ systems, developmental concerns, growth abnormalities or other features that can make conventional diagnostic approaches challenging.
The high diagnostic yield observed in these wards suggests that genomic disease may be underrecognized among hospitalized children who do not meet the typical profile for critical care genetic testing.
The findings could encourage hospitals to reconsider how they identify patients who may benefit from genomic testing.
Rather than limiting rGS to children experiencing acute, life-threatening illness, hospitals could potentially develop broader clinical criteria that include children with unexplained multisystem conditions, developmental concerns, persistent diagnostic uncertainty or unusual growth patterns.
Particularly Strong Results in Children With Faltering Growth
The study’s findings in children experiencing faltering growth were especially notable.
This group achieved a diagnostic yield of 63%, meaning that genetic testing identified a molecular diagnosis in nearly two-thirds of the children evaluated.
Researchers identified 37 different genetic diagnoses among 36 patients, while four patients were found to have two separate genetic diagnoses.
Faltering growth can have numerous potential causes, ranging from nutritional and gastrointestinal conditions to endocrine disorders, chronic illness and genetic disease. Because the clinical presentation can be nonspecific, an underlying genetic disorder may not always be recognized early.
Alexandra C. Keefe, MD, PhD, a clinical genetics physician at Seattle Children’s, said the high diagnostic yield in this population was particularly significant because children with faltering growth have not traditionally been viewed as obvious candidates for rapid genome sequencing.
The findings suggest that genomic testing could help identify genetic conditions in children who might otherwise remain outside conventional genetics referral pathways.
A diagnosis obtained during hospitalization can potentially influence immediate clinical management while also helping families understand the underlying cause of their child’s symptoms.
Potential Impact on Patient Management
A molecular diagnosis can have consequences that extend beyond simply giving a name to a disease.
For children with rare genetic disorders, a confirmed diagnosis can help physicians select appropriate treatments, determine which interventions may be ineffective, anticipate potential complications and establish appropriate monitoring strategies.
A diagnosis can also influence decisions regarding additional testing and specialist referrals.
For families, receiving a genetic diagnosis may provide an explanation for symptoms that have remained unresolved for months or years. It can also help inform discussions about recurrence risk, family testing and long-term care planning.
The benefits may be particularly significant for children with complex or multisystem conditions, where conventional diagnostic pathways can involve numerous appointments and tests.
By incorporating rapid genome sequencing into inpatient care, healthcare systems may be able to shorten these diagnostic journeys.
Reducing Pressure on Outpatient Genetics Services
The study also highlights potential operational advantages for healthcare systems.
Genetic medicine services in many healthcare systems face significant demand and limited specialist capacity. Patients can wait weeks or months for an outpatient genetics appointment, particularly when services are concentrated in major pediatric centers.
If genomic testing is performed during hospitalization when clinically appropriate, some diagnostic work can occur before discharge. This may reduce the number of patients who require outpatient genetics referrals solely to initiate diagnostic testing.
Hospital-wide rGS implementation could therefore help reduce bottlenecks in specialty care while allowing genetics teams to focus their resources on patients requiring more complex interpretation, counseling or management.
The researchers suggest that this model could be implemented without requiring a major expansion of genetics staffing.
This is an important consideration for health systems seeking to scale precision medicine. Expanding access to genomic testing does not necessarily have to mean creating large numbers of new specialist positions if testing pathways and clinical workflows are designed efficiently.
Addressing Health Equity
Another significant finding from the study involved equity in access to genetic testing.
The researchers found that hospital-wide implementation of rapid genome sequencing eliminated race-based disparities in access to testing.
This finding is particularly relevant as healthcare organizations increasingly examine differences in access to advanced diagnostic technologies.
Genomic medicine has the potential to improve diagnosis across diverse patient populations, but unequal access to testing can prevent some groups from benefiting from advances in precision medicine.
By making rGS broadly available across inpatient settings rather than relying solely on individual referrals or specialized clinical pathways, hospitals may be able to reduce barriers that contribute to disparities.
The study therefore suggests that hospital-wide implementation could potentially support not only improved diagnostic performance but also more equitable access to genomic medicine.
Creating a Scalable Model for Genomic Medicine
The findings from Seattle Children’s provide what GeneDx describes as a potential blueprint for integrating genomic testing more broadly into pediatric hospital care.
The study demonstrates that rapid genome sequencing can be implemented across multiple inpatient environments rather than being restricted to critical care units.
Such an approach could allow clinicians to identify genetic diseases earlier and potentially improve the efficiency of diagnostic pathways.
Linda Genen, MD, MPH, Chief Medical Officer at GeneDx and a former practicing neonatologist, said the study provides an important model for health systems seeking to make genomic medicine a more standard component of inpatient care.
According to Genen, expanding access to rGS in non-critical care units could help hospitals provide genomic answers to more children, reduce specialty-care bottlenecks and create a more scalable precision medicine model.
The findings are particularly relevant as genomic sequencing becomes increasingly accessible and healthcare organizations seek ways to incorporate molecular information into routine clinical decision-making.
Implications for the Future of Pediatric Genomic Testing
The Seattle Children’s experience may have implications for how hospitals identify candidates for genomic sequencing in the future.
Rather than considering rapid genome sequencing exclusively as an emergency diagnostic tool for critically ill newborns, health systems could potentially view it as a broader diagnostic resource for children with unexplained or complex medical conditions.
The study’s results indicate that meaningful diagnostic yields can be achieved among children outside intensive care, including those who may not have been recognized previously as likely candidates for genetic testing.
The particularly strong results in children with faltering growth also suggest that specific clinical presentations could be valuable triggers for genomic evaluation.
As hospitals develop genomic medicine programs, standardized pathways may allow physicians to identify appropriate candidates earlier and integrate sequencing into routine inpatient workflows.
Broader Significance for Rare Disease Diagnosis
Rare genetic diseases can be difficult to diagnose because individual conditions may affect only a small number of patients and often share symptoms with more common disorders.
Children may see multiple specialists before a genetic diagnosis is considered. In some cases, the underlying condition may not be recognized until symptoms become more severe.
Rapid genome sequencing can provide a comprehensive assessment of a patient’s genetic information and potentially identify disease-causing variants across a wide range of genes.
The ability to perform this testing quickly is particularly important in hospitalized children, where clinical decisions may need to be made within days rather than months.
The GeneDx-supported study adds to the growing evidence that genomic sequencing can have clinical value across a wider range of pediatric settings.
The publication of the Seattle Children’s study represents an important development in the expansion of genomic medicine across pediatric healthcare.
With more than 1,000 patients evaluated over 3.5 years, the study provides substantial real-world evidence supporting the implementation of first-tier rapid genome sequencing across multiple inpatient environments.
The 35% overall diagnostic yield, 43% yield in non-ICU inpatient wards and 63% yield among children evaluated for faltering growth highlight the potential value of expanding testing beyond traditional intensive care populations.
The identification of numerous genetic diagnoses, including cases involving dual diagnoses, demonstrates the ability of genomic testing to uncover complex underlying causes of pediatric disease.
At the health-system level, broader use of rGS could potentially reduce diagnostic delays, decrease pressure on outpatient genetics services and improve access to specialized genomic testing. The finding that hospital-wide implementation eliminated race-based disparities in access further underscores the potential of this approach to support more equitable healthcare delivery.
For patients and families, earlier genetic diagnosis can provide valuable information that may influence treatment, monitoring and long-term care. For clinicians, genomic results can offer new insights into otherwise unexplained conditions and help guide more informed medical decisions.
As genomic technologies continue to advance, the Seattle Children’s experience suggests that the future of pediatric precision medicine may involve making rapid genome sequencing available much earlier and across a broader range of clinical settings.
The study ultimately supports a shift from viewing genomic sequencing as a specialized service reserved for the most critically ill children toward considering it as an important first-tier diagnostic tool for hospitalized pediatric patients with unexplained or complex medical conditions. This broader model could help health systems deliver faster diagnoses, improve clinical decision-making and bring the benefits of precision medicine to more children living with rare and difficult-to-diagnose diseases.
About GeneDx
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx® tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses.
GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine.